Skip to main content

Advertisement

SpringerLink
Log in

Atorvastatin induces downregulation of matrix metalloproteinase-2/9 in MDA-MB-231 triple negative breast cancer cells

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Matrix metalloproteinases (MMPs) are a family of endopeptidases, mainly responsible of extracellular tissue remodeling. Abundant expression of MMPs leads to a number of tumorigenic processes including proliferation, angiogenesis, metastasis and invasion. Therefore, suppressing MMP expression is particularly important in cancer. Atorvastatin is a member of statin family, with cholesterol-lowering properties. Recently, it has emerged as a potential anticancer agent. Multiple researchers have reported promising results of atorvastatin use in cancer therapies. However, its effect on the expression of matrix metalloproteinases in breast cancer is unknown. In the present study, we have confirmed the apoptotic activity of atorvastatin on highly metastatic MDA-MB-231 triple negative breast cancer cells and investigated the gene expression of MMP-2/9. In this regard, MTT analysis was performed to evaluate cytotoxicity. Apoptotic activity was assessed by Annexin V binding and multicaspase assays. Western blot analysis was used to detect the apoptosis-related proteins. RT-PCR analysis was performed to evaluate the mRNA expression levels of MMP-2/9. Results indicated that atorvastatin reduces cell viability significantly at 5 µM after 48 h of treatment (p < 0.0001). It also induces caspase-dependent apoptosis, alters the expression of Bax and Bcl-2 in favour of apoptosis and stimulates cell cycle arrest at S phase (p < 0.05). Moreover, atorvastatin downregulates the mRNA expression of MMP-2 and MMP-9 significantly (p < 0.05). In conclusion, these results demonstrate for the first time that atorvastatin inhibits MMP-2 and MMP-9 gene expression in MDA-MB-231 cells, in addition to inducing caspase-dependent apoptosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

Data availability

The authors confirm that the data supporting the findings of this study are available from the corresponding author, upon reasonable request

References

  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.

    Article  Google Scholar 

  2. Kumar P, Aggarwal R. An overview of triple-negative breast cancer. Arch Gynecol Obstet. 2016;293(2):247–69.

    Article  CAS  Google Scholar 

  3. Matusewicz L, Meissner J, Toporkiewicz M, Sikorski AF. The effect of statins on cancer cells: review. Tumor Biol. 2015;36(7):4889–904.

    Article  CAS  Google Scholar 

  4. Zhang J, Yang Z, Xie L, Xu L, Xu D, Liu X. Statins, autophagy and cancer metastasis. Int J Biochem Cell Biol. 2013;45(3):745–52.

    Article  CAS  Google Scholar 

  5. Taylor F, Huffman MD, Macedo AF, Moore THM, Burke M, Davey Smith G, et al. Statins for the primary prevention of cardiovascular disease. Cochrane database Syst Rev. 2013;1:CD004816. https://doi.org/10.1002/14651858.CD004816.pub5.

    Article  Google Scholar 

  6. Siniscalchi C. Protective role of statins during anticoagulation for venous thromboembolism: beyond their lipid lowering effect? Eur J Intern Med. 2020;79:127–9. https://doi.org/10.1016/j.ejim.2020.04.026.

    Article  Google Scholar 

  7. Spence AD, Busby J, Hughes CM, Johnston BT, Coleman HG, Cardwell CR. Statin use and survival in patients with gastric cancer in two independent population-based cohorts. Pharmacoepidemiol Drug Saf. 2019;28(4):460–70.

    Article  CAS  Google Scholar 

  8. Oh TK, Kim K, Jheon S, Lee J, Do SH, Hwang JW, et al. Impact of statin use on recurrence or survival after surgical curative resection of non-small cell lung cancer. Cancer Control. 2018;25(1):1–6.

    Article  Google Scholar 

  9. Harborg S, Heide-Jørgensen U, Ahern TP, Ewertz M, Cronin-Fenton D, Borgquist S. Statin use and breast cancer recurrence in postmenopausal women treated with adjuvant aromatase inhibitors: a Danish population-based cohort study. Breast Cancer Res Treat. 2020;183(1):153–60. https://doi.org/10.1007/s10549-020-05749-5.

    Article  CAS  Google Scholar 

  10. Lacroix O, Couttenier A, Vaes E, Cardwell CR, De Schutter H, Robert A. Statin use after diagnosis is associated with an increased survival in esophageal cancer patients: a Belgian population-based study. Cancer Causes Control. 2019;30(4):385–93. https://doi.org/10.1007/s10552-019-01149-3.

    Article  Google Scholar 

  11. Ma Q, Gao Y, Xu P, Li K, Xu X, Gao J, et al. Atorvastatin inhibits breast cancer cells by downregulating PTEN/AKT pathway via promoting ras homolog family member B (RhoB). Biomed Res Int. 2019. https://doi.org/10.1155/2019/3235021.

    Article  Google Scholar 

  12. Toepfer N, Childress C, Parikh A, Rukstalis D, Yang W. Atorvastatin induces autophagy in prostate cancer PC3 cells through activation of LC3 transcription. Cancer Biol Ther. 2011;12(8):691–9.

    Article  CAS  Google Scholar 

  13. Kao LT, Hung SH, Kao PF, Liu JC, Lin HC. Inverse association between statin use and head and neck cancer: population-based case-control study in Han population. Head Neck. 2019;41(5):1193–8.

    Article  Google Scholar 

  14. Abdel-Rahman O. Statin treatment and outcomes of metastatic pancreatic cancer: a pooled analysis of two phase III studies. Clin Transl Oncol. 2019;21(6):810–6. https://doi.org/10.1007/s12094-018-1992-3.

    Article  CAS  Google Scholar 

  15. Kumar AS, Benz CC, Shim V, Minami CA, Moore DH, Esserman LJ. Estrogen receptor-negative breast cancer is less likely to arise among lipophilic statin users. Cancer Epidemiol Biomark Prev. 2008;17(5):1028–33.

    Article  CAS  Google Scholar 

  16. Hu MB, Zhang JW, Gao JB, Qi YW, Gao Y, Xu L, et al. Atorvastatin induces autophagy in MDA-MB-231 breast cancer cells. Ultrastruct Pathol. 2018;42(5):409–15. https://doi.org/10.1080/01913123.2018.1522406.

    Article  Google Scholar 

  17. Alarcon Martinez T, Zeybek ND, Müftüoğlu S. Evaluation of the cytotoxic and autophagic effects of atorvastatin on mcf-7 breast cancer cells. Balk Med J. 2018;35(3):256–62.

    Article  Google Scholar 

  18. Bayat N, Izadpanah R, Ebrahimi-Barough S, Javidan AN, Ai A, Ardakan MMM, et al. The anti-angiogenic effect of atorvastatin in glioblastoma spheroids tumor cultured in fibrin gel: in 3D in vitro model. Asian Pac J Cancer Prev. 2018;19(9):2553–60.

    CAS  Google Scholar 

  19. Bayat N, Ebrahimi-Barough S, Norouzi-Javidan A, Saberi H, Ardakan MMM, Ai A, et al. Anti-inflammatory effects of atorvastatin by suppressing TRAF3IP2 and IL-17RA in human glioblastoma spheroids cultured in a three-dimensional model: possible relevance to glioblastoma treatment. Mol Neurobiol. 2018;55(3):2102–10.

    Article  CAS  Google Scholar 

  20. Zhang L, Chen T, Dou Y, Zhang S, Liu H, Khishignyam T, et al. Atorvastatin exerts antileukemia activity via inhibiting mevalonate-YAP axis in K562 and HL60 cells. Front Oncol. 2019;9:1–13.

    Google Scholar 

  21. Ozkan E, Bakar-Ates F. The trinity of matrix metalloproteinases, inflammation, and cancer: a literature review of recent updates. Anti-inflamm Antiallergy Agents Med Chem. 2020;19(3):206–21.

    Article  CAS  Google Scholar 

  22. Wang HL, Zhou PY, Zhang Y, Liu P. Relationships between abnormal MMP2 expression and prognosis in gastric cancer: a meta-analysis of cohort studies. Cancer Biother Radiopharm. 2014;29(4):166–72.

    CAS  Google Scholar 

  23. Liu D, Zhang R, Wu J, Pu Y, Yin X, Cheng Y, et al. Interleukin-17A promotes esophageal adenocarcinoma cell invasiveness through ROS-dependent, NF-κB-mediated MMP-2/9 activation. Oncol Rep. 2017;37(3):1779–85.

    Article  CAS  Google Scholar 

  24. Kim ML, Sung KR, Kwon J, Shin JA. Statins suppress TGF-β2-mediated MMP-2 and MMP-9 expression and activation through RhoA/ROCK inhibition in astrocytes of the human optic nerve head. Investig Ophthalmol Vis Sci. 2020;61(5):29.

    Article  CAS  Google Scholar 

  25. Bakar-Ates F, Ozkan E, Sengel-Turk CT. Encapsulation of cucurbitacin B into lipid polymer hybrid nanocarriers induced apoptosis of MDAMB231 cells through PARP cleavage. Int J Pharm. 2020;586: 119565. https://doi.org/10.1016/j.ijpharm.2020.119565.

    Article  CAS  Google Scholar 

  26. He Y, Huarong H, Farischon C, Li D, Du Z, Kun Z, et al. Combined effects of atorvastatin and aspirin on growth and apoptosis in human prostate cancer cells. Oncol Rep. 2017;37(2):953–60.

    Article  CAS  Google Scholar 

  27. Chen Y-H, Chen Y-C, Liu C-S, Hsieh M-C. The different effects of atorvastatin and pravastatin on cell death and PARP activity in pancreatic NIT-1 cells. J Diabetes Res. 2016;2016:1–17.

    Google Scholar 

  28. Kang M, Jeong CW, Ku JH, Kwak C, Kim HH. Inhibition of autophagy potentiates atorvastatin-induced apoptotic cell death in human bladder cancer cells in vitro. Int J Mol Sci. 2014;15(5):8106–21.

    Article  Google Scholar 

  29. Sheng B, Song Y, Zhang J, Li R, Wang Z, Zhu X. Atorvastatin suppresses the progression of cervical cancer via regulation of autophagy. Am J Transl Res. 2020;12(9):5252–68.

    CAS  Google Scholar 

  30. O’Grady S, Crown J, Duffy MJ. Statins inhibit proliferation and induce apoptosis in triple-negative breast cancer cells. Med Oncol. 2022;39(10):142. https://doi.org/10.1007/s12032-022-01733-9.

    Article  CAS  Google Scholar 

  31. Bakar-Ates F, Ozkan E. The combined treatment of brassinin and imatinib synergistically downregulated the expression of MMP-9 in SW480 colon cancer cells. Phyther Res. 2019;33(2):397–402.

    Article  CAS  Google Scholar 

  32. Fromigué O, Hamidouche Z, Marie PJ. Blockade of the RhoA-JNK-c-Jun-MMP2 cascade by atorvastatin reduces osteosarcoma cell invasion. J Biol Chem. 2008;283(45):30549–56.

    Article  Google Scholar 

  33. Liu MW, Liu R, Wu HY, Chen M, Dong MN, Huang YQ, et al. Atorvastatin has a protective effect in a mouse model of bronchial asthma through regulating tissue transglutaminase and triggering receptor expressed on myeloid cells-1 expression. Exp Ther Med. 2017;14(2):917–30.

    Article  CAS  Google Scholar 

  34. Eliasson P, Svensson RB, Giannopoulos A, Eismark C, Kjær M, Schjerling P, et al. Simvastatin and atorvastatin reduce the mechanical properties of tendon constructs in vitro and introduce catabolic changes in the gene expression pattern. PLoS ONE. 2017;12(3):e0172797. https://doi.org/10.1371/journal.pone.0172797.

    Article  CAS  Google Scholar 

Download references

Funding

The authors declare that no funds, grants, or other support were received during the preparation of this manuscript.

Author information

Authors and Affiliations

  1. Faculty of Pharmacy, Department of Biochemistry, Ankara University, Anadolu, 06560, Ankara, Turkey

    Filiz Bakar-Ates & Erva Ozkan

Authors
  1. Filiz Bakar-Ates
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Erva Ozkan
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

FBA: Conceptualization, project administration, methodology, supervision, data curation, analysis, writing—review & editing. EO: Investigation, methodology, data curation, analysis, writing—original draft, writing—review & editing.

Corresponding author

Correspondence to Filiz Bakar-Ates.

Ethics declarations

Competing interests

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bakar-Ates, F., Ozkan, E. Atorvastatin induces downregulation of matrix metalloproteinase-2/9 in MDA-MB-231 triple negative breast cancer cells. Med Oncol 40, 22 (2023). https://doi.org/10.1007/s12032-022-01880-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-022-01880-z

Keywords

Search

Navigation